SCHEDULE: Vanguard Discloses AstraZeneca Stake

Vanguard Capital Management reports beneficial ownership of over 77.9 million shares, representing 5.02% of AstraZeneca PLC's common stock.

Summary

• Vanguard Capital Management, along with its affiliates, has filed a Schedule 13G indicating beneficial ownership of 77,965,099 shares of AstraZeneca PLC common stock.
• This holding represents 5.02% of the class of securities.
• Vanguard Capital Management exercises sole voting power over 32,924,957 shares and sole dispositive power over 77,965,099 shares.
• The filing is made in accordance with SEC Release No. 34-39538, reflecting securities held by Vanguard funds and managed accounts.
• The reporting date for this event is March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of institutional ownership rather than an announcement of company performance or strategy.

Positives

• Vanguard's significant stake suggests confidence in AstraZeneca's long-term prospects.
• The filing indicates that Vanguard funds and managed accounts have the right to receive dividends and proceeds from the sale of these shares, implying a direct financial interest.

Risks

• The filing does not explicitly mention any risks associated with this ownership stake.

Future Outlook

The filing itself is a historical disclosure of ownership and does not contain forward-looking statements or guidance from AstraZeneca.

Industry Context

StockSavvy.ai notes that large institutional investors like Vanguard filing Schedule 13G forms often signal significant, albeit passive, investment in a company. This filing indicates Vanguard's substantial position in the pharmaceutical sector, specifically within AstraZeneca's operations.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can influence market perception and trading dynamics.
• Vanguard Clients: The filing reflects the investment decisions made by Vanguard on behalf of its clients and funds.

Key Dates

Keywords

AstraZeneca PLC, Vanguard Capital Management, Schedule 13G, Common Stock, Beneficial Ownership, Securities Filing, Investment Management